Abstracts tagged "race/ethnicity"

Abstract Number: 0196 • ACR Convergence 2024
Associations Between Systemic Lupus Erythematosus (SLE) and the Social Vulnerability Index (SVI)
Zoe Reed¹, Xana Howard¹, Cristina Arriens¹, Teresa Aberle¹, Wade DeJager², Joan Merrill³ and Judith James¹, ¹Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Oklahoma Medical Research Foundation, Oklahoma City, ³Oklahoma Medical Research Foundation, Oklahoma City 73104, OK
Background/Purpose: Systemic lupus erythematosus (SLE) is a complex autoimmune disease that disproportionately affects young women of certain racial and ethnic minority groups with enhanced severity…
Abstract Number: 1337 • ACR Convergence 2024
Gender and Ethnic Differences (or Lack Thereof) in Perceived Disease Burden in RA
Ali Malik¹, Dennis Ang¹, Adam Hall¹, John Herion¹ and Rupak Thapa², ¹Wake Forest University, Winston Salem, NC, ²Assistant Professor, Winston Salem, NC
Background/Purpose: Gender and ethnic disparities in health care are well reported in the general medical literature. Differences in symptom reporting or perceived health status can…
Abstract Number: 2589 • ACR Convergence 2024
A Nationwide Analysis of Risk of Acute Coronary Syndrome in RA Patients with Interstitial Lung Disease
Omair Khan¹, Azka Naeem², Kundan Jana², Syed Mujtaba Baqir², Tharun Shyam² and Saumya Nanda², ¹Maimonides Medical Center, Council Bluffs, IA, ²Maimonides Medical Center, Brooklyn, NY
Background/Purpose: Rheumatoid Arthritis (RA) and Interstitial Lung Disease (ILD) are systemic inflammatory conditions that independently increase the risk of Acute Coronary Syndrome (ACS). However, there…
Abstract Number: 0210 • ACR Convergence 2024
Rheumatology, Heal Thyself: The Experience of Underrepresented Physicians in Rheumatology
Rob Valdovinos¹, Ashley Martin², Jay Mehta² and Irene Blanco³, ¹UCSF Benioff Children's Hospital, San Francisco, CA, ²Children's Hospital of Philadelphia, Philadelphia, PA, ³Northwestern University, Oak Park, IL
Background/Purpose: Providing racially and ethnically concordant care in minoritized populations by providers identifying as underrepresented in medicine (URiM) has been reported to be associated with…
Abstract Number: 1404 • ACR Convergence 2024
Modeling Diversity in Systemic Lupus Erythematosus (SLE) Clinical Trials Using Real-world Data (RWD) Sources
Andrew Bevan¹ and Nora Carroll², ¹Integrated Project Solutions, PPD, part of Thermo Fisher Scientific, Cambridge, United Kingdom, ²Cardiovascular and General Medicine, Thermo Fisher Scientific, Athlone, Ireland
Background/Purpose: The FDA places emphasis on studying clinically relevant trial populations but does not address how these might be defined. SLE disproportionately affects women and…
Abstract Number: PP12 • ACR Convergence 2024
Healing Together: The Role of Black, Indigenous and People of Color (BIPOC) -Only Chronic Illness Spaces in Comprehensive Care
Sarah Shaw and JP Summers, Global Healthy Living Foundation, Upper Nyack, NY
Background/Purpose: As someone from the Black, Indigenous, and People of Color (BIPOC) community living with rheumatic conditions, I have experienced firsthand many challenges that people…
Abstract Number: 0297 • ACR Convergence 2024
Characteristics of Adult-Onset Still’s Disease Skin Eruption in Individuals of Sub-Saharan Ancestry
Benoit Suzon¹, Eleonore de Fritsch¹, Arthur Felix¹, Fabienne Louis-sidney², Emmanuelle Amazan¹, Florence Moinet³, Aurore Abel¹, Illitch Coco-Viloin¹, Moustapha Dramé¹, Christophe Deligny⁴ and Pernelle Thomas¹, ¹University Hospital of Martinique, Fort-de-France, Martinique, ²University Hospital Martinique, Fort De France, Martinique, ³University Hospital of Martinique, Fort de France, France, ⁴University Hospital of Martinique - National reference center for autoimmune disease, Internal Medicine, Fort-de-France, Martinique
Background/Purpose: There is no data about adult-onset Still's disease (AOSD) skin eruption in individuals of sub-Saharan ancestry, from basic description to potential clinical implications.Methods: We conducted…
Abstract Number: 1747 • ACR Convergence 2024
Native Americans Experience Profound Premature Mortality from Rheumatoid Arthritis
Parmita Das¹, Snehin Rajkumar², Eric Yen³ and Ram Singh⁴, ¹University of California Los Angeles, Saint Johns, ²UCLA David Geffen School of Medicine, Irvine, CA, ³UCLA, Los Angeles, CA, ⁴UCLA David Geffen School of Medicine, Los Angeles, CA
Background/Purpose: Rheumatoid Arthritis (RA) is a chronic debilitating disease affecting up to 1% of the US population and has variable outcomes by race/ethnicity. We analyzed…
Abstract Number: 0353 • ACR Convergence 2024
Identifying Solutions to Address Racial and Ethnic Health Disparities in Lupus: A Consensus-Based Approach
Joy Buie¹, Michael Fisher¹, Hannah Tlydsley², Kristen Backor² and Karen Costenbader³, ¹Lupus Foundation of America, Washington, DC, ²Charles River Associates, San Francisco, CA, ³Brigham and Women's Hospital/ Harvard Medical School, Boston, MA
Background/Purpose: Health disparities among racial and ethnic minoritized individuals living with lupus remain a critical public health concern. Challenges related to healthcare affordability, accessibility, and…
Abstract Number: 1803 • ACR Convergence 2024
Genetics of eGFR Variability as a Proxy for Lupus Nephritis in Patients with Systemic Lupus Erythematosus
Magdalena Riedl Khursigara¹, Nicholas Gold², Thai-Son Tang³, JingJing Cao⁴, Daniela Dominguez⁴, Marisa Klein-Gitelman⁵, Dafna Gladman⁶, Daniel Goldman⁷, Elizabeth Harvey⁴, Mariko Ishimori⁸, Caroline Jefferies⁹, Diane Kamen¹⁰, Sylvia Kamphuis¹¹, Andrea Knight¹², Chia-Chi Lee¹³, Deborah Levy², Damien Noone⁴, Karen Onel¹⁴, Christine Peschken¹⁵, Michelle Petri⁷, Janet Pope¹⁶, Eleanor Pullenayegum⁴, Earl Silverman¹⁷, Zahi Touma¹⁸, Murray Urowitz¹⁹, Daniel Wallace²⁰, Joan Wither²¹ and Linda Hiraki², and Systemic Lupus Erythematosus Collaborative Clinics (SLICC), ¹University of Toronto, Cambridge, MA, ²The Hospital for Sick Children, Toronto, ON, Canada, ³University of Toronto, Mississauga, ON, Canada, ⁴The Hospital for Sick Children, Toronto, Canada, ⁵Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, ⁶University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ⁷Johns Hopkins University School of Medicine, Timonium, MD, ⁸Cedars-Sinai Health System, Los Angeles, CA, ⁹Cedars-Sinai Medical Center, Beverly Hills, CA, ¹⁰Medical University of South Carolina, Charleston, SC, ¹¹Erasmus University Medical Center, Rotterdam, Netherlands, ¹²Division of Rheumatology, The Hospital for Sick Children; Neurosciences and Mental Health, SickKids Research Institute; Department of Paediatrics, University of Toronto, Toronto, ON, Canada, ¹³Cedars-Sinai Medical Center, Los Angeles, CA, ¹⁴HSS, New York, NY, ¹⁵University of Manitoba, Winnipeg, MB, Canada, ¹⁶University of Western Ontario, London, ON, Canada, ¹⁷Silverman, Toronto, ON, Canada, ¹⁸University of Toronto, Toronto, ON, Canada, ¹⁹Self employed, Toronto, ON, Canada, ²⁰Cedars Sinai Medical Center, Studio City, CA, ²¹University Health Network, Toronto, ON, Canada
Background/Purpose: Lupus nephritis (LN) is one of the most common and severe manifestations of systemic lupus erythematosus (SLE). We performed genome wide association studies (GWAS)…
Abstract Number: 0645 • ACR Convergence 2024
Mortality and Ethnicity in Adults with Systemic Lupus Erythematosus: A Systematic Literature Review and Meta-Analysis
Samir Patel¹, Zijing Yang¹, deepak Nagra¹, Maryam Adas², Mark Russell¹, Sam Norton¹, Chris Wincup³, James Galloway⁴, Kate Bramham² and Patrick Gordon⁵, ¹King's College London, London, England, United Kingdom, ²King's College London, London, United Kingdom, ³King's College Hospital, London, United Kingdom, ⁴Centre for Rheumatic Diseases, King's College London, London, United Kingdom, ⁵nhs, London, United Kingdom
Background/Purpose: Ethnicity and health outcomes are intrinsically interrelated, although mechanisms are complex. Systemic lupus erythematosus (SLE) is a disease with higher incidence in non-White populations…
Abstract Number: 1907 • ACR Convergence 2024
Community-Engaged Curriculum Development Using Racial Justice and Biomedical Lenses to Address COVID-19 Vaccine Hesitancy in Black Individuals with Rheumatologic Conditions
Eseosa Osaghae¹, Greta Sirek², Tonya Roberson³, Mia Chandler⁴, Ariel Childs⁵, Monica Crespo-Bosque⁶, Gina Curry⁷, Amar Dhand⁸, Mary Dollear⁹, Alice Eggleston¹⁰, Nnenna Ezeh², Dieufort Fleurissaint¹¹, Denice Garrett¹², Gail Granville¹³, Muriel Jean-Jacques¹, Elena Losina², Holly Milaeger¹, Lutfiyya Muhammad¹⁴, Mary Ann Nelson¹⁵, Chisa Nosamiefan¹⁶, Bisola Ojikutu¹⁷, Neil Pillai¹, Marie Jacques Toussaint¹⁸, Mary Beth Son¹⁹, Ana Valle², Jessica Williams²⁰, Michael York²¹, Karen Mancera-Cuevas²², Candace Feldman² and rosalind Ramsey-Goldman¹, ¹Northwestern University, Chicago, IL, ²Brigham and Women's Hospital, Boston, MA, ³Governors State University College of Health and Human Services, University Park, IL, ⁴Boston Children’s Hospital, Boston, MA, ⁵Vital CxNs, Boston, MA, ⁶Boston Medical Center, Boston, MA, ⁷University of Chicago Pritzker School of Medicine, Chicago, IL, ⁸Brigham and Women’s Hospital, Boston, MA, ⁹Lupus Society of Illinois, Chicago, IL, ¹⁰Alliance Chicago, Chicago, IL, ¹¹True Alliance Center, Inc, Boston, MA, ¹²Action for Bridgeport Community Development, Inc., Bridgeport, CT, ¹³Women of Courage, Inc, Boston, MA, ¹⁴Northwestern Feinberg School of Medicine, Chicago, IL, ¹⁵Mission Hill Health Movement Inc, Roxbury, MA, ¹⁶The Labalaba Foundation for Lupus Awareness and Advocacy, South Weymouth, MA, ¹⁷Harvard Medical School, Brigham and Women’s Hospital, Boston Public Health Commission,, Boston, MA, ¹⁸True Alliance Center, Inc., Boston, MA, ¹⁹Boston Children's Hospital, Brookline, MA, ²⁰Emory School of Medicine, Atlanta, GA, ²¹Boston University, Boston, MA, ²²National Health Council, Washington, DC
Background/Purpose: Despite the efficacy of COVID-19 vaccines and the benefits for individuals with rheumatic conditions, racial inequities in uptake persist. We initiated a trial that…
Abstract Number: 0847 • ACR Convergence 2024
Sex and Race-Specific Distributions in Medial Fixed Joint Space Width in Healthy Knees from Three Longitudinal Cohorts
Kent Kwoh¹, Rongrong Tang², Erin Ashbeck³, Edward Bedrick⁴, Yvonne Golightly⁵, Amanda Nelson⁶, Tuhina Neogi⁷, Yong Ge⁸, Zong-Ming Li², Jean Liew⁷, Xiaoxiao Sun⁹, Justin Crawmer¹⁰ and Jeffery Duryea¹¹, ¹University of Arizona, Tucson, AZ, ²University of Arizona Arthritis Center, University of Arizona College of Medicine - Tucson, Tucson, AZ, ³University of Arizona Mel and Enid Zuckerman College of Public Health, Tucson, AZ, ⁴Department of Epidemiology andBiostatistics, Mel and Enid Zuckerman College of Public Health, University of Arizona, Tucson, ⁵University of Nebraska Medical Center, Omaha, NE, ⁶University of North Carolina at Chapel Hill, Chapel Hill, NC, ⁷Boston University Chobanian & Avedisian School of Medicine, Boston, MA, ⁸Department of Information Sciences, Eller College of Manangement, University of Arizona, Tucson, AZ, ⁹Department of Biostatistics, Mel and Enid Zuckerman College of Public Health, University of Arizona, Tucson, AZ, ¹⁰BWH, Boston, MA, ¹¹Brigham and Women’s Hospital, Harvard Medical School, Boston, MA
Background/Purpose: Quantitative radiographic joint space width (JSW) is often used as ameasure of structural outcomes in randomized controlled trials of knee OA (KOA). How JSW…
Abstract Number: 1914 • ACR Convergence 2024
Racial and Ethnic Differences in the Prevalence of Disease Features in Systemic Sclerosis
Harry Hurley¹, Davina Chen², Xianhong Xie³, Manpreet Parmar⁴ and Bibi Ayesha⁵, ¹Albert Einstein College of Medicine, Maplewood, NJ, ²Montefiore Medical Center, New Rochelle, NY, ³Albert Einstein College of Medicine, Bronx, NY, ⁴Montefiore, Bronx, NY, ⁵Montefiore Medical Center, Metuchen, NJ
Background/Purpose: Systemic sclerosis (SSc) is a chronic, systemic autoimmune disease with a higher prevalence among women and racial/ethnic minority groups in the US. Despite the…
Abstract Number: 0115 • ACR Convergence 2024
Regional and Ethnoracial Differences Among Antiphospholipid Antibody-Positive Patients with No Other Systemic Autoimmune Rheumatic Diseases: Results from AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Registry
Elena Gkrouzman¹, Ann E. Clarke², Maria Tektonidou³, Vittorio Pengo⁴, Savino Sciascia⁵, Jose Pardos-Gea⁶, Nina Kello⁷, Diana Paredes-Ruiz⁸, Mª Angeles Aguirre-Zamorano⁹, H Michael Belmont¹⁰, Paul Fortin¹¹, Guilherme Ramires de Jesús¹², Tatsuya Atsumi¹³, Zhuoli Zhang¹⁴, Maria Efthymiou¹⁵, David Branch¹⁶, Giulia Pazzola¹⁷, Laura Andreoli¹⁸, Ali Duarte-Garcia¹⁹, Esther Rodriguez-Almaraz²⁰, Michelle Petri²¹, Ricard Cervera²², Bahar Artim Esen²³, Guillermo Pons-Estel²⁴, Hui Shi²⁵, Jason Knight²⁶, Rohan Willis²⁷, Pierluigi Meroni²⁸, Maria Laura Bertolaccini²⁹, Hannah Cohen³⁰, Robert Roubey³¹, Danieli Andrade³² and Doruk Erkan³³, and on behalf of APS ACTION, ¹University of Massachusetts, Westborough, MA, ²Division of Rheumatology, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, ³National and Kapodistrian University of Athens, Athens, Greece, ⁴Thrombosis Research Laboratory, Department of Cardio-Thoracic-Vascular Sciences and Public Health, University of Padova, Padova, Italy, ⁵University of Turin, Torino, Turin, Italy, ⁶Vall d'Hebron University Hospital, Barcelona, Spain, ⁷Northwell Health, Brooklyn, NY, ⁸Autoimmune Diseases Research Unit. Biocruces Bizkaia Health Research Institute, Baracaldo, Spain, ⁹IMIBIC/Reina Sofia Hospital/University of Cordoba, CÓRDOBA, Andalucia, Spain, ¹⁰NYU School of Medicine, New York, NY, ¹¹Centre ARThrite - CHU de Québec - Université Laval, Quebec, QC, Canada, ¹²Universidade do Estado do Rio de Janeiro, Rio De Janeiro, Brazil, ¹³Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan, Sapporo, Japan, ¹⁴Peking University First Hospital, Beijing, China, ¹⁵University College London, London, United Kingdom, ¹⁶University of Utah and Intermountain Healthcare, Salt Lake City, UT, ¹⁷Rheumatology Unit, Azienda USL IRCCS di Reggio Emilia, Reggio Emilia, Italy, ¹⁸University of Brescia, Brescia, Italy, ¹⁹Mayo Clinic, Rochester, MN, ²⁰Hospital Universitario 12 de Octubre, Madrid, Spain, ²¹Johns Hopkins University School of Medicine, Timonium, MD, ²²Hospital Clinic de Barcelona, Barcelona, Spain, ²³Istanbul University, Istanbul Faculty of Medicine, Division of Rheumatology, Istanbul, Turkey, ²⁴CREAR, Rosario, Argentina, ²⁵Department of Rheumatology and lmmunology, Ruijin Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China, Shanghai, China (People's Republic), ²⁶University of Michigan, Ann Arbor, MI, ²⁷University of Texas Medical Branch, Galveston, TX, ²⁸IRCCS Istituto Auxologico Italiano 100%, Cusano Milanino, Milan, Milan, Italy, ²⁹King's College London, London, United Kingdom, ³⁰University College London Hospitals NHS Foundation Trust, London, United Kingdom, ³¹Division of Rheumatology, Allergy, and Immunology, University of North Carolina, Chapel Hill, NC, ³²University of São Paulo, São Paulo, SP, Brazil, ³³Hospital for Special Surgery, New York, NY
Background/Purpose: The APS ACTION Registry was created to study long-term outcomes in persistently antiphospholipid antibody (aPL)-positive patients with and without other systemic autoimmune rheumatic diseases…

1
2
3
…
14
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].